Versant Venture Management 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
Adverum Biotechnologies, Inc.	Common Stock	00773U108	17,739	5,068,233	SH		OTR		0	5,068,233	0
Akero Therapeutics, Inc.	Common Stock	00973Y108	15,326	617,727	SH		OTR		0	617,727	0
Aligos Therapeutics, Inc.	Common Stock	01626L105	47,301	2,320,381	SH		OTR		0	2,320,381	0
Aprea Therapeutics, Inc	Common Stock	03836J102	6,147	1,259,662	SH		OTR		0	1,259,662	0
Clovis Oncology, Inc.	Common Stock	189464100	591	101,855	SH		OTR		0	101,855	0
Crinetics Pharmaceuticals, Inc.	Common Stock	22663K107	15,471	820,720	SH		OTR		0	820,720	0
CRISPR Therapeutics AG	Common Shares	H17182108	82,330	508,558	SH		OTR		0	508,558	0
CymaBay Therapeutics, Inc.	Common Stock	23257D103	2,371	543,753	SH		OTR		0	543,753	0
Flexion Therapeutics, Inc.	Common Stock	33938J106	8,230	1,000,000	SH		OTR		0	1,000,000	0
Gritstone Oncology, Inc.	Common Stock	39868T105	40,634	4,450,638	SH		OTR		0	4,450,638	0
Passage Bio, Inc.	Common Stock	702712100	65,667	4,959,769	SH		OTR		0	4,959,769	0